Using gene expression data for susceptible and resistant tumors, Genstruct built a model of cancer biology and used it to define the mechanisms of activity and resistance for a compound of interest.

Impact: supplied key information for go/no go in development of compound, including biomarkers for efficacy and resistance.

Using gene expression data from mechanistically distinct patient populations, Genstruct built a model for breast cancer. This model was then used to identify novel drug targets that can intervene in the progression and maintenance of breast cancer in the population of interest.

Impact: discovered novel switches that may be a key regulator of the disease, and defined specific targets to advance new breast cancer drug discovery program.

Using gene expression, proteomics and metabonomics data, Genstruct developed a model for drug-induced toxicity in animals and used it to define the toxicity mechanism for a class of compounds.

Impact: delivered mechanisms for drug-induced toxicity and biomarkers for identifying toxicity in the clinic, as well as identified a more appropriate animal model for drug testing.

Using a very large set of gene expression, proteomics and metabonomics data from multiple tissues, serum and urine, Genstruct developed a model of lipid metabolism and related biology and used it to define the molecular mechanisms of efficacy for a clinical compound.

Impact: defined molecular mechanisms and clinical biomarkers for compound mechanisms and facilitated clinical decision point.